nach oben

Tipp

Circulating bioactive sclerostin levels in an Austrian population-based cohort

Zeitschrift:: Wiener klinische Wochenschrift

Autoren:: Katharina Kerschan-Schindl, Ursula Föger-Samwald, Andreas Gleiss, Stefan Kudlacek, Jacqueline Wallwitz, Peter Pietschmann

» Zum Volltext PDF-Version jetzt herunterladen

Wichtige Hinweise

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Summary

Background

Circulating serum sclerostin levels are supposed to give a good estimation of the levels of this negative regulator of bone mass within bone. Most studies evaluating total serum sclerostin found different levels in males compared to females and in older compared to younger subjects. Besides an ELISA detecting total sclerostin an ELISA determining bioactive sclerostin has been developed. The aim of this study was to investigate serum levels of bioactive sclerostin in an Austrian population-based cohort.

Methods

We conducted a cross-sectional observational study in 235 healthy subjects. Using the bioactive ELISA assay (Biomedica) bioactive sclerostin levels were evaluated.

Results

Serum levels of bioactive sclerostin were higher in men than in women (24%). The levels correlated positively with age (r = 0.47). A positive correlation could also be detected with body mass index and bone mineral density.

Conclusion

Using the ELISA detecting bioactive sclerostin our results are consistent with data in the literature obtained by different sclerostin assays. The determination of sclerostin concentrations in peripheral blood thus appears to be a robust parameter of bone metabolism.

Unsere Produktempfehlungen

Abo für kostenpflichtige Inhalte

Jetzt informieren

Van Buchem FS, Hadders HN, Ubbens R. An uncommon familial systemic disease of the skeleton: hyperostosis corticalis generalisata familiaris. Acta Radiol. 1995;4:109–20.

Truswell AS. Osteopetrosis with syndactyly, a morphologic variant of Albers-Schönberg disease. J Bone Joint Surg. 1958;40:208–18. CrossRef

Semenov M, Tamai K, He X. SOST is a ligand for LRP5/6 and a Wnt signaling inhibitor. J Biol Chem. 2005;260:770–5.

Drake MT, Srinivasan B, Mödder UI, Peterson JM, McCready LK, Riggs BL, et al. Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. J Clin Endocrinol Metab. 2010;95:5056–62. CrossRef

Farr JN, Roforth MM, Fujita K, Nicks KM, Cunningham JM, Atkinson EJ, et al. Effects of age and estrogen on skeletal gene expression in humans as assessed by RNA sequencing. Plos One. 2015;10:e138347. CrossRef

Mödder UI, Clowes JA, Hoey K, Peterson JM, McCready L, Oursler MJ, et al. Regulation of circulating sclerostin levels by sex steroids in women and in men. J Bone Miner Res. 2011;26:27–43. CrossRef

Dovjak P, Dorfer S, Föger-Samwald U, Kudlacek S, Marculescu R, Pietschmann P. Serum levels of sclerostin and dickkopf1: effects of age, gender and fracture status. Gerontology. 2014;60:493–501. CrossRef

Wanby P, Nobin R, Von SP, Brudin L, Carlsson M. Serum levels of the bone turnover markers dickkopf‑1, sclerostin, osteoprotegerin, osteopontin, osteocalcin and 25-hydroxyviatimin D in Swedish ’geriatric patients aged 75 years or older with a fresh hip fracture in healthy controls. J Endocrinol Invest. 2016;39:855–63. CrossRef

Moriwaki K, Matsumoto H, Tanishima S, Tanimura C, Osaki M, Nagashima H, et al. Association of serum bone- and muscle-derived factors with age, sex, body composition, and physical function in community-dwelling middle-aged and elderly adults: a cross-sectional study. BMC Musculoskelet Disord. 2019;20:276. https://doi.org/10.1186/s12891-019-2650-9. CrossRefPubMedPubMedCentral

10.

Xu XJ, Shen L, Yang YP, Lu FR, Zhu R, Shuai B, et al. Serum sclerostin levels associated with lumbar spine bone mineral density and bone turnover markers in patients with postmenopausal osteoporosis. Chin Med J. 2013;126:2480–4. PubMed

11.

Amrein K, Amrein S, Drexler C, Dimai HP, Dobnig H, Pfeifer K, et al. Sclerostin and its association with physical activity, age, gender, body composition, and bone mineral content in healthy adults. J Clin Endocrinol Metab. 2012;97:48–54.

12.

Ardawi MS, Rouzi AA, Al-Sibiani SA, Al-Senani NS, Qari MH, Mousa SA. High sclerostin predicts the occurrence of osteoporotic fractures in postmenopausal women: the center of excellence for osteoporosis research study. J Bone Miner Res. 2012;27:2592–602. CrossRef

13.

Gunsser J, Hermann R, Roth A, Lupp A. Comprehensive assessment of tissue and serum parameters of bone metabolism in a series of orthopaedic patients. Plos One. 2019;14:e227133. CrossRef

14.

Xu Y, Gao C, He J, Gu W, Yi C, Chen B, et al. Sclerostin and its associations with bone metabolism markers and sex hormones in healthy community-dwelling elderly individuals an adolescents. Front Cell Dev Biol. 2020;8:57. https://doi.org/10.3389/fcell.2020.00057. CrossRefPubMedPubMedCentral

15.

Wallwitz J, Gadermaier E, Berg G, Himmler G. Comparison of the new bioactive Sclerostin ELISA with other commercially available Sclerostin immunoassays. (Abstract). Calcif Tissue Int. 2018;102:S1–S159. https://doi.org/10.1007/s00223-018-0418-0. CrossRef

16.

Maimoun L, Bouallègue BF, Gelis A, Aouinti S, Mura T, Philibert P, et al. Periostin and sclerostin levels in individuals with spinal cord injury and their relationship with bone mass, bone turnover, fracture and osteoporosis status. Bone. 2019;127:612–9. CrossRef

17.

Wakolbinger R, Muschitz C, Wallwitz J, Bodlaj G, Feichtinger X, Schanda JE, et al. Serum levels of sclerostin reflect altered bone microarchitecture in patients with hepatic cirrhosis. Wien Klin Wochenschr. 2020;132:19–26. CrossRef

18.

Kudlacek S, Schneider B, Woloszczuk W, Pietschmann P, Willvonseder R, Austrian Study Group on Normative Values of Bone Metabolism. Serum levels of osteoprotegerin increase with age in a healthy adult population. Bone. 2003;32:681–6. CrossRef

19.

Bhattoa HP, Wamwaki J, Kalina E, Foldesi R, Balogh A, Antal-Szalmas P. Serum sclerostin levels in healthy men over 50 yars of age. J Bone Miner Metab. 2013;31:579–84. CrossRef

20.

Rauner M, Sipos W, Pietschmann P. Age-dependent Wnt gene expression in bone and during the course of osteoblast differentiation. Age. 2008;30:273–82. CrossRef

21.

He J, Zhang H, Wang C, Zhang Z, Yue H, Hu W, et al. Associations of serum sclerostin and polymorphisms in the SOST gene with BMD and markers of bone metabolism in postmenopausal Chinese women. J Clin Endocrinol Metab. 2014;99:E655–E73.

22.

Kalem MN, Kalem Z, Akgun N, Bakirarar B. The relationship between postmenopausal women’s sclerostin levels and their bone density, age, body mass index, hormonal status, and smoking and consumption of coffee and dairy products. Arch Gynecol Obstet. 2017;295:785–93. CrossRef

23.

Garnero P, Sornay-Rendu E, Munoz F, Borel O, Chapurlat RD. Association of serum sclerostin with bone mineral density, bone turnover, steroid and parathyroid hormones, and fracture risk in postmenopausal women: the OFELY study. Osteoporos Int. 2013;24:489–94. CrossRef

24.

Szulc P, Bertholon C, Borel O, Marchand F, Charpurlat P. Lower fracture risk in older men with higher sclerostin concentration: a prospective analysis from the MINOS study. J Bone Miner Res. 2013;28:855–64. CrossRef

25.

Föger-Samwald U, Vekszler G, Hörz-Schuch E, Salem S, Wipperich M, Titschl P, et al. Molecular mechanisms of osteoporotic hip fractues in elderly women. Exp Gerontol. 2016;73:49–58. CrossRef

26.

Amrein K, Dobnig H, Wagner D, Piswanger-Sölkner C, Pieber TR, Pilz S, et al. Sclerostin in institutionalized elderly women associations with quantitative bone ultrasound, bone turnover, fractures, and mortality. J Am Geriatr Soc. 2014;62:1023–9. CrossRef

27.

Tartaglione L, Pasquali M, Rotondi S, Muci ML, Leonangeli C, Farcomeni A, et al. nteractions of sclerostin with FGF23, soluble klotho and vitamin D in renal transplantation. PLoS One. 2017;12:e178637. CrossRef

28.

Czajkowska M, Plinta R, Owczarek A, Olszanecka-Glinianowicz M, Skrzypulec-Plinta V. Circulating sclerostin levels in relation to nutritional status, sex hormones and selected bone turnover markers levels in peri- and postmenopausal women. Ginekol Pol. 2019;90:371–5. CrossRef

Titel: Circulating bioactive sclerostin levels in an Austrian population-based cohort
Autoren:: Katharina Kerschan-Schindl
Ursula Föger-Samwald
Andreas Gleiss
Stefan Kudlacek
Jacqueline Wallwitz
Peter Pietschmann
Publikationsdatum: 05.02.2021
DOI: https://doi.org/10.1007/s00508-021-01815-0
Verlag: Springer Vienna
Zeitschrift: Wiener klinische Wochenschrift The Central European Journal of Medicine
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671

Springer Medizin Österreich